标题
A Critical Review of the Efficacy and Safety of Inclisiran
作者
关键词
-
出版物
American Journal of Cardiovascular Drugs
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-05-06
DOI
10.1007/s40256-021-00477-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeting LDL cholesterol: Early treatment is key to population health
- (2020) Jane Stock ATHEROSCLEROSIS
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
- (2020) David Sinning et al. Current Cardiology Reports
- Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial
- (2019) Michelle L. O'Donoghue et al. CIRCULATION
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
- (2019) Donna K. Arnett et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels
- (2019) Kausik K. Ray et al. JAMA Cardiology
- Inclisiran—New hope in the management of lipid disorders?
- (2019) Krzysztof Dyrbuś et al. Journal of Clinical Lipidology
- Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies
- (2019) R. Scott Wright et al. MAYO CLINIC PROCEEDINGS
- Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants
- (2019) Nelson Wang et al. Lancet Diabetes & Endocrinology
- Role of PCSK9 in lipid metabolism and atherosclerosis
- (2018) Xiao-Long Lin et al. BIOMEDICINE & PHARMACOTHERAPY
- PCSK9 inhibition in the management of familial hypercholesterolemia
- (2018) Masatsune Ogura Journal of Cardiology
- Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial
- (2018) Lawrence A. Leiter et al. DIABETES CARE
- Safety and efficacy of statin therapy
- (2018) Bhavin B. Adhyaru et al. Nature Reviews Cardiology
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
- (2018) Constantine E. Kosmas et al. Patient Preference and Adherence
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Limitations of cholesterol lowering with PCSK9 inhibitors
- (2017) Gilbert Thompson Lancet Diabetes & Endocrinology
- Familial Hypercholesterolemia—Epidemiology, Diagnosis, and Screening
- (2015) Siddharth Singh et al. Current Atherosclerosis Reports
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started